Cargando…
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We used plasma from 20 unvaccinated and 7 vaccinated individuals infected by Omicr...
Autores principales: | Richardson, Simone I., Madzorera, Vimbai Sharon, Spencer, Holly, Manamela, Nelia P., van der Mescht, Mieke A., Lambson, Bronwen E., Oosthuysen, Brent, Ayres, Frances, Makhado, Zanele, Moyo-Gwete, Thandeka, Mzindle, Nonkululeko, Motlou, Thopisang, Strydom, Amy, Mendes, Adriano, Tegally, Houriiyah, de Beer, Zelda, Roma de Villiers, Talita, Bodenstein, Annie, van den Berg, Gretha, Venter, Marietjie, de Oliviera, Tulio, Ueckermann, Veronica, Rossouw, Theresa M., Boswell, Michael T., Moore, Penny L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947963/ https://www.ncbi.nlm.nih.gov/pubmed/35436444 http://dx.doi.org/10.1016/j.chom.2022.03.029 |
Ejemplares similares
-
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
por: Kitchin, Dale, et al.
Publicado: (2022) -
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022) -
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022) -
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022) -
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)